BITCOIN PRICES SLIDE Bitcoin prices were lower on Wednesday, as selling in the cryptocurrency resumed a day

BITCOIN SURGES PAST $3,500 AS RALLY CONTINUES

BITCOIN SURGES PAST $3,500 AS RALLY CONTINUES

Bitcoin surged to all-time highs on Friday, as investors remained

Bitcoin surged to all-time highs on Friday, as investors remained optimistic about Bitcoin’s future amid bullish comments from analysts.

On the U.S.-based Bitfinex exchange, bitcoin rose to $3,525.9, up $109.7 or 3.21%, surging past its previous all-time high of $3482.9.

Sentiment on Bitcoin turned positive, following last week’s ‘hard fork’ which split the blockchain supporting bitcoin into two, creating a rival digital currency called Bitcoin Cash, as analysts continued to talk up the prospect of cryptocurrencies.



Bitcoin surged

“Whether or not you believe in the merit of investing in cryptocurrencies (you know who you are), real dollars are at work here and warrant watching.” Goldman Sachs (NYSE:GS) noted in its question-and-answer report focused on cryptocurrencies.

Bitcoin Cash followed Bitcoin’s move higher, rising 13.44% to $329.53.

Bitcoin Cash seeks to increase bitcoin’s block size to eight megabytes whereas SegWit short for “segregated witness” proposes to move some of the data outside of the main bitcoin network to speed up transactions.

SegWit, seen as a milestone for Bitcoin, is expected to be implemented within two weeks.

Meanwhile, Ethereum, rose by 2% to $302.31.

|Chart | Calendar   | TRADE NOW | FORCAST | cryptocurrency 

Market Quotes by TradingView

Like up on FACEBOOK


logo

( ethereum logoETH )  (bitcoin logo BTC )  ( ripple logo XRP )  (  litecoin logoLTC )  (DASH LOGO  DASH )  ( NEM LOGO NEM ) ( ethereum-classic LOGO ETC )



 

BITCOIN SETS SIGHTS ON $3,500 Bitcoin pared losses sustained in the prior session to trade near all-time highs,

BITCOIN SETS SIGHTS ON $3,500 AS RALLY RESUMES

BITCOIN SETS SIGHTS ON $3,500 AS RALLY RESUMES

BITCOIN SETS SIGHTS ON $3,500 Bitcoin pared losses sustained in the prior session to trade near all-time highs,

BITCOIN SETS SIGHTS ON $3,500 Bitcoin pared losses sustained in the prior session to trade near all-time highs, as a key software upgrade, aimed at speeding up transactions on the network, nears implementation.

On the U.S.-based Bitfinex exchange, bitcoin rose to $3,422.4, up $63.8 or 1.90%, just shy of Tuesday’s high of $3482.9, following the adoption of BIP 91, a software upgrade that seeks to introduce something known as SegWit2X was adopted by the blockchain supporting bitcoin.

SegWit is short for “segregated witness” and proposes to move some of the data outside the main bitcoin network to increase its capacity, speeding up transaction on the bitcoin network.



BITCOIN SETS SIGHTS

The SegWit rollout, which will take two weeks to fully implement, is seen as a milestone for Bitcoin.

Bitcoin Cash followed Bitcoin’s move lower, easing 10.5% to $290.34.

Bitcoin Cash, was created as a result of a ‘civil war’ in Bitcoin, after some members of the bitcoin community rejected software upgrade SegWit2x on the back of concerns that the measure fails to adequately address bitcoin’s scaling problem.

Bitcoin transactions are limited to one megabyte every 10 minutes – or seven transactions per second. This compares to 2,000 per second for Visa and means that at peak times bitcoin transactions can take hours to be fulfilled, inhibiting the currency.

Bitcoin Cash seeks to increase the block size to eight megabytes whereas SegWit2X proposes moving transaction data outside of the block on a parallel track with plans to increase bitcoin’s block size later in the year.

Meanwhile, Ethereum, hit one-month highs rising about 2% to $310.05.

|Chart | Calendar   | TRADE NOW | FORCAST | cryptocurrency 

Market Quotes by TradingView

Like up on FACEBOOK


logo

( ethereum logoETH )  (bitcoin logo BTC )  ( ripple logo XRP )  (  litecoin logoLTC )  (DASH LOGO  DASH )  ( NEM LOGO NEM ) ( ethereum-classic LOGO ETC )



INVESTORSBUZ PRESS RELEASE Valeant says plaque psoriasis drug Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that following the evaluation and approval of its Patient Access and Pricing Committee

Valeant says plaque psoriasis drug will cost $3,500 a month

Valeant’s Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis

INVESTORSBUZ PRESS RELEASE Valeant says plaque psoriasis drug Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that following the evaluation and approval of its Patient Access and Pricing Committee

INVESTORSBUZ PRESS RELEASE Valeant says plaque psoriasis drug Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), the company has decided to list SILIQ™ (brodalumab) injection, at $3,500 per month, which is the lowest injectable biologic psoriasis treatment currently on the market. SILIQ will also be included in the company’s patient access program to further offer financial support and access to patients.  SILIQ, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. SILIQ is the only product that included the psoriasis area and severity index (PASI 100) during clinical trials as a primary endpoint. The sales and marketing of SILIQ are expected to commence in the U.S. during the second half of 2017.

“The Patient Access and Pricing Committee was constructed to help our company ensure patients have the best possible access to our products. Our goal with SILIQ is to provide outstanding efficacy while being the most affordable injectable biologic for patients with moderate-to-severe plaque psoriasis,” said Joseph Papa, Chairman and CEO of Valeant.




 Valeant says plaque psoriasis drug

In May 2016, Valeant established the PAPC to be responsible for the pricing of the company’s drugs. The PAPC ensures that Valeant’s pricing, contracting, compliance and reimbursement strategies are consistent and compliant with all relevant laws, regulations and guidance, as well as the company’s position on patient-affordable access to medicines. The Company’s Board of Directors oversees the committee, which is chaired by Papa and includes a multi-disciplinary team of Valeant employees, including doctors, scientists, and other executives.

SILIQ has a Black Box Warning for risk in patients with a history of suicidal thoughts or behavior. SILIQ was approved with a Risk Evaluation and Mitigation Strategy (REMS) involving a one-time enrollment for physicians and one-time informed consent for patients. The most common adverse reactions were headache, arthralgia, fatigue, oropharyngeal pain, and diarrhea. SILIQ is contraindicated in patients with Crohn’s disease.  Suicidal ideation and behavior have been reported. Serious infections have occurred therefore caution should be exercised when considering the use of SILIQ in patients with a chronic infection or a history of recurrent infection. Patients should be evaluated for tuberculosis infection prior to initiating treatment.

About SILIQ

In February 2017, the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SILIQ, a novel human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by preventing the binding of several types of IL-17 to the receptor. By blocking IL-17 from activating the receptor, SILIQ prevents the body from receiving signals that may lead to inflammation. The IL-17 pathway plays a central role in inducing and promoting inflammatory disease processes.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Like up on FACEBOOK


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )